Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT04426825 | A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 2 | 23 | Hoffmann-La RocheINDUSTRY | 1 | May 21, 2024 |
| NCT03001882 | An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)(CheckMate 592) | completed | Phase 2 | 230 | Bristol-Myers SquibbINDUSTRY | 8 | May 20, 2024 | clinicaltrials |
| NCT02978196 | 99mTc/68Ga Labeled Anti-PD-L1 sdAb in Assessment of PD-L1 Expression in NSCLC | completed | Early Phase 1 | 34 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT02910999 | Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy(ENLARGE-Lung) | completed | — | 868 | Bristol-Myers SquibbINDUSTRY | 1 | May 13, 2024 | clinicaltrials |
| NCT01941316 | Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients | completed | Phase 1 / Phase 2 | 78 | Cancer Research and Biostatistics Clinical Trials ConsortiumNETWORK | 1 | May 9, 2024 | clinicaltrials |
| NCT03712969 | Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC | completed | Phase 4 | 527 | West China HospitalOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT03810066 | Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS) | completed | Phase 2 | 16 | University Hospital, EssenOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT04263090 | Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment | completed | Phase 1 / Phase 2 | 25 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT01851369 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | May 8, 2024 | clinicaltrials |
| NCT02225405 | Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer | completed | Phase 1 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT04324437 | eRAPID: Online Symptom Reporting in Lung Cancer | completed | N/A | 43 | University of LeedsOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT03117049 | Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52) | completed | Phase 3 | 550 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 3 | May 6, 2024 | clinicaltrials |
| NCT03946007 | Quality of Life and Physical Fitness After Immune Checkpoint Inhibitors | completed | — | 134 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01928576 | Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.(NA_00084192) | completed | Phase 2 | 143 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT02658097 | Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT02760225 | Pembrolizumab-PET Imaging | completed | N/A | 18 | University Medical Center GroningenOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT04967079 | Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients | completed | Phase 1 | 33 | Shanghai Chest HospitalOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT00728390 | A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks | completed | Phase 1 | 74 | PfizerINDUSTRY | 3 | Apr 22, 2024 | clinicaltrials |
| NCT02118415 | Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT) | completed | Phase 2 | 13 | Technical University of MunichOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT03861156 | D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer | completed | Phase 2 | 290 | InventisBio Co., LtdINDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT03490669 | Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors | completed | Phase 1 | 41 | AstraZenecaINDUSTRY | 3 | Apr 5, 2024 | clinicaltrials |
| NCT04511533 | Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations | completed | Phase 4 | 101 | PfizerINDUSTRY | 1 | Apr 5, 2024 | clinicaltrials |
| NCT04979988 | Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients | completed | — | 51 | PfizerINDUSTRY | 1 | Apr 5, 2024 | clinicaltrials |
| NCT03866993 | A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer | completed | Phase 3 | 350 | AkesoINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT03076164 | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | completed | Phase 1 / Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03958097 | Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer | completed | Phase 2 | 20 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04501497 | Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2) | completed | — | 1,221 | Chugai PharmaceuticalINDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04818983 | The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2) | completed | — | 470 | Chugai PharmaceuticalINDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06339554 | Alectinib-induced Endocrine Toxicity(TOSS-ALK) | completed | — | 98 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT01761240 | Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Mar 29, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT02581787 | SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 28 | Maximilian DiehnOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06331975 | Radiomics and Radiogenomics of Non-small Cell Lung Cancer | completed | N/A | 91 | European Institute of OncologyOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT03017885 | Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy | completed | — | 28 | Boehringer IngelheimINDUSTRY | 1 | Mar 25, 2024 | clinicaltrials |
| NCT03590054 | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 35 | Rahul AggarwalOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT02337530 | Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC | completed | Phase 2 | 62 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 21, 2024 | clinicaltrials |
| NCT02414139 | Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) | completed | Phase 2 | 373 | Novartis PharmaceuticalsINDUSTRY | 20 | Mar 20, 2024 | clinicaltrials |
| NCT04212052 | Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 104 | Sun Yat-sen UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03535363 | Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC | completed | Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT03607188 | Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer(NSCLC) | completed | Phase 1 | 17 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04310943 | Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma | completed | Phase 2 | 24 | Zhou ChengzhiOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT00019006 | Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00020202 | FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03976518 | Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)(CHANCE) | completed | Phase 2 | 43 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT01540045 | Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer | completed | — | 40 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04238169 | Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC | completed | Phase 2 | 60 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05005273 | A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 1 | Bristol-Myers SquibbINDUSTRY | 12 | Feb 28, 2024 | clinicaltrials |
| NCT02869685 | Consistency Analysis of PD-L1s in Advanced NSCLC Tissues and in Plasma Exosomes Before and After Radiotherapy(RadImm02) | completed | N/A | 60 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT02890849 | Clinical Research for the Consistency Analysis of PD-L1 in Cancer Tissue and Plasma Exosome(RadImm01) | completed | N/A | 60 | Xinqiao Hospital of ChongqingOTHER | 0 | Feb 23, 2024 | clinicaltrials |
Data updated 24 days agoSource updated May 24, 2024source: clinicaltrials